AChE Inhibition-based Multi-target-directed Ligands, a Novel Pharmacological Approach for the Symptomatic and Disease-modifying Therapy of Alzheimer's Disease

Overview

Journal Curr Neuropharmacol

Publisher Bentham Science Publishers

Date 2016 Jan 21

PMID 26786145

Citations 24

Authors

Yu Wang

Hao Wang

Hong-Zhuan Chen

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is the most common form of dementia in elder people, characterised by a progressive decline in memory as a result of an impairment of cholinergic neurotransmission. To date acetylcholinesterase inhibitors (AChEIs) have become the most prescribed drugs for the symptomatic treatment of mild to moderate AD. However, the traditional "one molecule-one target" paradigm is not sufficient and appropriate to yield the desired therapeutic efficacy since multiple factors, such as amyloid-β (Aβ) deposits, neuroinflammation, oxidative stress, and decreased levels of acetylcholine (ACh) have been thought to play significant roles in the AD pathogenesis. New generation of multi-target drugs is earnestly demanded not only for ameliorating symptoms but also for modifying the disease. Herein, we delineated the catalytic and non-catalytic functions of AChE, and summarized the works of our group and others in research and development of novel AChEI-based multi-target-directed ligands (MTDLs), such as dual binding site AChEIs and multitarget AChEIs inhibiting Aβ aggregation, regulating Aβ procession, antagonizing platelet-activating factor (PAF) receptor, scavenging oxygen radical, chelating metal ions, inhibiting monoamine oxidase B (MAO-B), blocking N-methyl-D-aspartic acid (NMDA) receptor and others.

Citing Articles

Computational identification of potential acetylcholinesterase (AChE) and monoamine oxidase-B inhibitors from : a case study of Alzheimer's disease (AD).

Sofela S, Ibrahim A, Ogbodo U, Bodun D, Nwankwo D, Mafimisebi M In Silico Pharmacol. 2024; 12(1):49.

PMID: 38828442 PMC: 11143168. DOI: 10.1007/s40203-024-00214-3.

The Unveiling of Therapeutic Targets for Alzheimer's Disease: An Integrative Review.

Madar P, Nagalapur P, Chaudhari S, Sharma D, Koparde A, Buchade R Curr Top Med Chem. 2024; 24(10):850-868.

PMID: 38424435 DOI: 10.2174/0115680266282492240220101049.

Multi-Target-Directed Cinnamic Acid Hybrids Targeting Alzheimer's Disease.

Drakontaeidi A, Pontiki E Int J Mol Sci. 2024; 25(1).

PMID: 38203753 PMC: 10778916. DOI: 10.3390/ijms25010582.

Scaling the Andean Shilajit: A Novel Neuroprotective Agent for Alzheimer's Disease.

Andrade V, Wong-Guerra M, Cortes N, Pastor G, Gonzalez A, Calfio C Pharmaceuticals (Basel). 2023; 16(7).

PMID: 37513872 PMC: 10383824. DOI: 10.3390/ph16070960.

Methoxy-naphthyl-Linked -Benzyl Pyridinium Styryls as Dual Cholinesterase Inhibitors: Design, Synthesis, Biological Evaluation, and Structure-Activity Relationship.

Abdullaha M, Banoo R, Nuthakki V, Sharma M, Kaur S, Thakur S ACS Omega. 2023; 8(20):17591-17608.

PMID: 37251153 PMC: 10210183. DOI: 10.1021/acsomega.2c08167.

References

Bachovchin D, Cravatt B . The pharmacological landscape and therapeutic potential of serine hydrolases. Nat Rev Drug Discov. 2012; 11(1):52-68. PMC: 3665514. DOI: 10.1038/nrd3620. View

Parameshwaran K, Dhanasekaran M, Suppiramaniam V . Amyloid beta peptides and glutamatergic synaptic dysregulation. Exp Neurol. 2007; 210(1):7-13. DOI: 10.1016/j.expneurol.2007.10.008. View

Duan S, Guan X, Lin R, Liu X, Yan Y, Lin R . Silibinin inhibits acetylcholinesterase activity and amyloid β peptide aggregation: a dual-target drug for the treatment of Alzheimer's disease. Neurobiol Aging. 2015; 36(5):1792-807. DOI: 10.1016/j.neurobiolaging.2015.02.002. View

Cheng S, Zheng W, Gong P, Zhou Q, Xie Q, Yu L . (-)-Meptazinol-melatonin hybrids as novel dual inhibitors of cholinesterases and amyloid-β aggregation with high antioxidant potency for Alzheimer's therapy. Bioorg Med Chem. 2015; 23(13):3110-8. DOI: 10.1016/j.bmc.2015.04.084. View

Ezoulin M, Li J, Wu G, Dong C, Ombetta J, Chen H . Differential effect of PMS777, a new type of acetylcholinesterase inhibitor, and galanthamine on oxidative injury induced in human neuroblastoma SK-N-SH cells. Neurosci Lett. 2005; 389(2):61-5. DOI: 10.1016/j.neulet.2005.07.026. View

Rosini M, Simoni E, Minarini A, Melchiorre C . Multi-target design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces. Neurochem Res. 2014; 39(10):1914-23. DOI: 10.1007/s11064-014-1250-1. View

Zhou W, Zhu X, Zhu L, Cui Y, Wang H, Qi H . Neuroprotection of muscarinic receptor agonist pilocarpine against glutamate-induced apoptosis in retinal neurons. Cell Mol Neurobiol. 2008; 28(2):263-75. PMC: 11516528. DOI: 10.1007/s10571-007-9251-0. View

Luo Z, Sheng J, Sun Y, Lu C, Yan J, Liu A . Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen. J Med Chem. 2013; 56(22):9089-99. DOI: 10.1021/jm401047q. View

Bansode S, Jana A, Batkulwar K, Warkad S, Joshi R, Sengupta N . Molecular investigations of protriptyline as a multi-target directed ligand in Alzheimer's disease. PLoS One. 2014; 9(8):e105196. PMC: 4139341. DOI: 10.1371/journal.pone.0105196. View

10.

Heppner F, Ransohoff R, Becher B . Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015; 16(6):358-72. DOI: 10.1038/nrn3880. View

11.

Tarozzi A, Bartolini M, Piazzi L, Valgimigli L, Amorati R, Bolondi C . From the dual function lead AP2238 to AP2469, a multi-target-directed ligand for the treatment of Alzheimer's disease. Pharmacol Res Perspect. 2014; 2(2):e00023. PMC: 4184701. DOI: 10.1002/prp2.23. View

12.

Morphy R, Rankovic Z . The physicochemical challenges of designing multiple ligands. J Med Chem. 2006; 49(16):4961-70. DOI: 10.1021/jm0603015. View

13.

Xie Q, Wang H, Xia Z, Lu M, Zhang W, Wang X . Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008; 51(7):2027-36. DOI: 10.1021/jm070154q. View

14.

Leon R, Garcia A, Marco-Contelles J . Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease. Med Res Rev. 2011; 33(1):139-89. DOI: 10.1002/med.20248. View

15.

Inestrosa N, Alvarez A, Perez C, Moreno R, Vicente M, Linker C . Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron. 1996; 16(4):881-91. DOI: 10.1016/s0896-6273(00)80108-7. View

16.

Cheung T, Song T, Ng T, Wu F, Lao L, Tang S . Therapeutic Effects of Herbal Chemicals in Traditional Chinese Medicine on Alzheimer's Disease. Curr Med Chem. 2015; 22(19):2392-403. DOI: 10.2174/0929867322666150520095509. View

17.

Wang H, Lu Y, Chen H . Differentiating effects of anisodamine on cognitive amelioration and peripheral muscarinic side effects induced by pilocarpine in mice. Neurosci Lett. 2003; 344(3):173-6. DOI: 10.1016/s0304-3940(03)00444-0. View

18.

Marco-Contelles J, Leon R, de Los Rios C, Samadi A, Bartolini M, Andrisano V . Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease. J Med Chem. 2009; 52(9):2724-32. DOI: 10.1021/jm801292b. View

19.

Bate C, Kempster S, Williams A . Platelet-activating factor antagonists protect amyloid-beta damaged neurons from microglia-mediated death. Neuropharmacology. 2006; 51(2):173-81. DOI: 10.1016/j.neuropharm.2006.02.015. View

20.

Shao B, Xia Z, Xie Q, Ge X, Zhang W, Sun J . Meserine, a novel carbamate AChE inhibitor, ameliorates scopolamine-induced dementia and alleviates amyloidogenesis of APP/PS1 transgenic mice. CNS Neurosci Ther. 2013; 20(2):165-71. PMC: 6493081. DOI: 10.1111/cns.12183. View